Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
المؤلف | AlMukdad, Sawsan |
المؤلف | Elewa, Hazem |
المؤلف | Al-Badriyeh, Daoud |
تاريخ الإتاحة | 2020-04-06T07:04:32Z |
تاريخ النشر | 2020 |
اسم المنشور | Journal of Cardiovascular Pharmacology and Therapeutics |
المعرّف | http://dx.doi.org/10.1177/1074248420902298 |
الاقتباس | AlMukdad, S., Elewa, H., & Al-Badriyeh, D. (2020). Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics, 25(3), 201–211. https://doi.org/10.1177/1074248420902298 |
الرقم المعياري الدولي للكتاب | 1074-2484 |
الملخص | Clopidogrel is widely used after the percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) and requires activation by cytochrome P450 (CYP), primarily CYP2C19. Patients with CYP2C19 loss-of-function alleles are at increased risk of major adverse cardiovascular events, while more expensive novel antiplatelet agents (ticagrelor and prasugrel) are unaffected by the CYP2C19 mutations. This systematic review aims to answer the question about whether overall evidence supports the genotype-guided selection of antiplatelet therapy as a cost-effective strategy in post-PCI ACS. A systematic literature search of PubMed, EMBASE, EconLit, and PharmGKB was done to identify all the economic evaluations related to genotype-guided therapy compared to the universal use of antiplatelets in ACS patients. Quality of Health Economic Studies tool was used for quality assessment. The search identified 13 articles, where genotype-guided treatment was compared to universal clopidogrel, ticagrelor, and/or prasugrel. Six studies showed that genotype-guided therapy was cost-effective compared to universal clopidogrel, while 5 studies showed that it was dominant. One study specified that genotype-guided with ticagrelor is cost-effective only in both CYP2C19 intermediate and poor metabolizers. Genotype-guided therapy was dominant when compared to universal prasugrel, ticagrelor, or both in 5, 1, and 3 studies, respectively. Only 2 studies reported that universal ticagrelor was cost-effective compared to genotype-guided treatment. All the included articles had good quality. Based on current economic evaluations in the literature, implementing CYP2C19 genotype-guided therapy is a cost-effective approach in guiding the selection of medication in patients with ACS undergoing PCI. |
اللغة | en |
الناشر | SAGE Publications |
الموضوع | CYP2C19 genotype clopidogrel cost-effectiveness percutaneous coronary intervention prasugrel ticagrelor |
النوع | Article |
الصفحات | 201-211 |
رقم العدد | 3 |
رقم المجلد | 25 |
ESSN | 1940-4034 |
الملفات في هذه التسجيلة
الملفات | الحجم | الصيغة | العرض |
---|---|---|---|
لا توجد ملفات لها صلة بهذه التسجيلة. |
هذه التسجيلة تظهر في المجموعات التالية
-
أبحاث الصيدلة [1243 items ]